Order Article Reprints

Dowling GP, Hegarty A, Daly GR, Hembrecht S, Hehir CM, Calpin GG, Hogan R, O’Reilly D, Downey E, Toomey S, et al. Prognostic Significance of Delays in Initiation of Adjuvant Trastuzumab-Based Therapy in Patients with HER2-Positive Breast Cancer. Biomedicines. 2025; 13(6):1305. https://doi.org/10.3390/biomedicines13061305

Dowling, Gavin P., Aisling Hegarty, Gordon R. Daly, Sandra Hembrecht, Cian M. Hehir, Gavin G. Calpin, Richard Hogan, David O’Reilly, Eithne Downey, Sinead Toomey, and et al. 2025. "Prognostic Significance of Delays in Initiation of Adjuvant Trastuzumab-Based Therapy in Patients with HER2-Positive Breast Cancer" Biomedicines 13, no. 6: 1305. https://doi.org/10.3390/biomedicines13061305

Dowling, G. P., Hegarty, A., Daly, G. R., Hembrecht, S., Hehir, C. M., Calpin, G. G., Hogan, R., O’Reilly, D., Downey, E., Toomey, S., Grogan, L., Breathnach, O., Allen, M., Morris, P. G., Power, C., Young, L. S., Hill, A. D. K., & Hennessy, B. T. (2025). Prognostic Significance of Delays in Initiation of Adjuvant Trastuzumab-Based Therapy in Patients with HER2-Positive Breast Cancer. Biomedicines, 13(6), 1305. https://doi.org/10.3390/biomedicines13061305